Status:
COMPLETED
Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Lead Sponsor:
Beijing 302 Hospital
Conditions:
Liver Cirrhosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is...
Detailed Description
Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is...
Eligibility Criteria
Inclusion
- Liver cirrhosis
- Negative pregnancy test (female patients in fertile age)
- written consent
Exclusion
- Hepatocellular carcinoma or other malignancies
- Pregnancy
- sepsis
- Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)
- Cardiac, renal or respiratory failure
- Active thrombosis of the portal or hepatic veins
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT01220492
Start Date
May 1 2009
End Date
April 1 2016
Last Update
August 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 Hospital
Beijing, Beijing Municipality, China, 100039